Alteration of microbiota antibody-mediated immune selection contributes to dysbiosis in inflammatory bowel diseases

EMBO Mol Med. 2022 Aug 8;14(8):e15386. doi: 10.15252/emmm.202115386. Epub 2022 Jul 4.

Abstract

Human secretory immunoglobulins (SIg) A1 and SIgA2 guide mucosal responses toward tolerance or inflammation, notably through reverse-transcytosis, the apical-to-basal transport of IgA2 immune complexes via M cells of gut Peyer's patches. As such, the maintenance of a diverse gut microbiota requires broad affinity IgA and glycan-glycan interaction. Here, we asked whether IgA1 and IgA2-microbiota interactions might be involved in dysbiosis induction during inflammatory bowel diseases. Using stool HPLC-purified IgA, we show that reverse-transcytosis is abrogated in ulcerative colitis (UC) while it is extended to IgA1 in Crohn's disease (CD). 16S RNA sequencing of IgA-bound microbiota in CD and UC showed distinct IgA1- and IgA2-associated microbiota; the IgA1+ fraction of CD microbiota was notably enriched in beneficial commensals. These features were associated with increased IgA anti-glycan reactivity in CD and an opposite loss of reactivity in UC. Our results highlight previously unknown pathogenic properties of IgA in IBD that could support dysbiosis.

Keywords: IBD; SIgA; glycosylation; immunity; microbiota.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colitis, Ulcerative* / pathology
  • Crohn Disease* / pathology
  • Dysbiosis
  • Humans
  • Immunoglobulin A
  • Inflammatory Bowel Diseases*

Substances

  • Immunoglobulin A